Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
7
A Scalable Blood-based Pancreatic Cancer Test for High-Risk Screening
Award last edited on: 2/22/2019
Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$227,001
Award Phase
1
Solicitation Topic Code
NCI
Principal Investigator
David Freedman
Company Information
nanoView Diagnostics Inc
(
AKA
: Nanoview Biosciences)
1380 Soldiers Field Road Suite 1000
Boston, MA 02135
(781) 365-8439
N/A
www.nanoviewdx.com
Location:
Single
Congr. District:
07
County:
Suffolk
Phase I
Contract Number:
1R43CA213863-01A1
Start Date:
5/2/2017
Completed:
10/31/2019
Phase I year
2017
Phase I Amount
$225,001
Pancreatic cancer is the fourth leading cause of cancer death in the US and is estimated to become the second leading cause of cancer deaths in the US by The high mortality rate is a direct result of early clinical diagnosis being difficult because initial symptoms of the disease are often nonspecific If pancreatic cancer is detected early the average five year relative survival rate increases fold Tools to detect the disease at the early stage are needed to improve outcomes There are no clinically validated biomarkers for early detection of pancreatic cancer but studies have shown that exosomes can serve as a perfect blood based test that and that this biomarker has the potential to be used for pancreatic cancer screening Despite the identification of this powerful biomarker tools to translate this test into a scalable workflow are still lacking nanoView Diagnostics NVDX has developed an optical sensing technique that can enumerate these circulating biomarkers directly from sample The NVDX platform is capable of detecting many different targets from a small volume of blood using a simple workflow and inexpensive consumables NVDX will establish that a pancreatic test can achieve high sensitivity and specificity in a relatively large number of early stage pancreatic cancer samples and also demonstrate that the assay is reproducible across a number of sensor manufacturing runs The second aim test the developed assay with blinded samples to detect early stage pancreatic cancer and results will be compared to clinical diagnosis Completion of the phase I work will position NVDX to pursue clinical validation of the exosome based PDAC assay In a phase II proposal NVDX will establish standard operating procedures for the assay for user independent performance The automated NVDX platform will be tested with patients to validate performance and demonstrate clinical utility The success of the SBIR research would enable nanoView Diagnostics to run multi center clinical trials for commercialization of a pancreatic screening test NARRATIVE PI Freedman David Scott Institution nanoView Diagnostics Inc Pancreatic cancer is the fourth leading cause of cancer death in the US and is estimated to become the second leading cause of cancer deaths in the US by The high mortality rate is a direct result of early clinical diagnosis being difficult because initial symptoms of the disease are often nonspecific Tools to detect the disease at the early stage are needed to improve outcomes and advance therapy developments We will use a scalable inexpensive and automated platform to demonstrate that a simple blood based test can be used to detect early stage pancreatic cancer
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
$2,000
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.